Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706391 · ClinicalTrials.gov registry record
Study of ALS Reversals 4: LifeTime Exposures
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 25
- Enrollment target
NCT03706391 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 25 participants.
The verdict
NCT03706391 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Hypothesis: There exists patients who have met ALS or PMA diagnostic criteria and subsequently experienced robust and sustained improvement, i.e. a "reversal." Thirty-eight of these patients were identified in the prior Duke University study, Documentation of Known ALS Reversals (St.A.R. Protocol 1, Duke IRB Pro00076395). The investigators hypothesize these patients have had different environmental exposures than patients with typically progressive ALS. Identification of specific environmental influences may point to exposures which are protective or exposure that lead to the development of a rare and novel reversible ALS-like disease. Objective: This study seeks to identify environmental exposures associated with ALS reversals.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2020-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03706391
The ClinicalTrials.gov registry entry for NCT03706391 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03706391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03706391 about?
NCT03706391 is a clinical study titled "Study of ALS Reversals 4: LifeTime Exposures". Hypothesis: There exists patients who have met ALS or PMA diagnostic criteria and subsequently experienced robust and sustained improvement, i.e. a "reversal." Thirty-eight of these patients were identified in the prior Duke University study, Documentation of Known ALS Reversals (St.A.R. Protocol 1,...
What is the current status of trial NCT03706391?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2018-09-26. Estimated completion is 2020-06-01.
Who is sponsoring clinical trial NCT03706391?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.